Form 4: Diane G. Gerst Reports Acquisition of Amphastar Pharmaceuticals Stock and Stock Options

Diane G. Gerst, a director at Amphastar Pharmaceuticals, reports acquiring common stock and stock options on June 3, 2024.

Summary

• On June 3, 2024, Diane G. Gerst, a director of Amphastar Pharmaceuticals, acquired 3,076 shares of common stock and 6,864 stock options.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $42.25 and expire on June 3, 2034.
• Following the transaction, Gerst directly owns 18,634 shares of common stock and 6,864 stock options.
• The restricted stock units vest on June 3, 2025, as do the shares subject to the option.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of stock and options by a director can be seen as a mildly positive signal, but it's not a major event.

Positives

• A director's acquisition of company stock and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring these transactions can provide insights into management's sentiment about the company's prospects.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies, including those in the pharmaceutical sector.
• Comparing the size and frequency of insider transactions at Amphastar to those of its peers (e.g., Teva Pharmaceutical Industries, Mylan, or Hikma Pharmaceuticals) can provide a relative perspective.
• The vesting schedules and exercise prices of stock options are also standard metrics to compare across companies to assess executive compensation and alignment with shareholder interests.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates